Key Facts Surrounding This News Item
- ARGX had returned 0.00% year-to-date leading up to today’s news, versus a +5.96% return from the benchmark S&P 500 during the same period.
More Info About argenx SE (ARGX)
arGEN-X N.V., a clinical-stage biopharmaceutical company, focuses on creating and developing therapeutic antibodies for the treatment of cancer and autoimmune diseases. The company was founded in 2008 and is based in Breda, Netherlands. View our full ARGX ticker page with ratings, news, and more.